Docoh
Loading...

TECH Bio-Techne



 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
 

 
FORM 8-K
 
 

 
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): April 30, 2020
 
 

 
BIO-TECHNE CORPORATION
(Exact Name of Registrant as Specified in its Charter)
 
Minnesota
0-17272
41-1427402
(State or Other Jurisdiction of
Incorporation)
(Commission File Number)
(I.R.S. Employer Identification
Number)
 
614 McKinley Place NE
Minneapolis, Minnesota 55413
(Address of Principal Executive Offices) (Zip Code)
 
(612) 379-8854
(Registrant’s Telephone Number, Including Area Code)
 
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common StockTECHNASDAQ
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 


 

 
Item 2.02 Results of Operations and Financial Condition
 
A copy of the press release issued by Bio-Techne Corporation on April 30, 2020, describing the results of operations for the quarter ended March 31, 2020 and its financial condition as of March 31, 2020, is attached hereto as Exhibit 99.1.
 
The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
 
 
Item 8.01 Other Events
 
A copy of the press release issued by Bio-Techne Corporation on April 30, 2020, announcing a cash dividend is attached hereto as Exhibit 99.2.
 
 
Item 9.01 Financial Statements and Exhibits
 
(d) Exhibits
 
 99.1
   
 99.2
   
 104 -Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 BIO-TECHNE CORPORATION 
    
Date: April 30, 2020By:/s/ Brenda S. Furlow 
 Brenda S. Furlow 
 Senior Vice President, General Counsel and Secretary
 
 
EXHIBIT INDEX
 
 Exhibit No.Description
   
 99.1Press Release, dated April 30, 2020, announcing results of operations
   
 99.2Press Release, dated April 30, 2020, announcing cash dividend.
   
 104 -Cover Page Interactive Data File (embedded within the Inline XBRL document)